Extended Data Fig. 8: Tracking TIL-derived T cell clones in baseline and post-treatment progressive tumors.
a, Cumulative frequency of infused TIL clonotypes in tumors from Clinical Benefit (n = 6 for baseline tumors, n = 5 for post-treatment tumors) vs. No-Benefit patients (n = 10 for baseline tumors, n = 7 for progressive tumors). b, Frequency of tumor-reactive T cell clones in time-serial tumors from Clinical Benefit (n = 4 tumors with identified TIL-recognized tumor antigens) vs. No-Benefit patients (n = 2 tumors with identified TIL-recognized tumor antigens). One-sided Mann–Whitney U-test was performed for the comparison. ns, not significant. Bars indicate median with range. c, Composition of different functional T cell subsets among KRASG12V/TP53G244C neoantigen-specific TIL vs other tumor antigen-specific TIL vs non-specific TIL. d, Transcriptomic expression of CD8 T cell subset signatures comparing KRASG12V/TP53G244C neoantigen-specific TIL vs non-specific TIL. The bar value shows fold change for each gene. e, Peripheral tracking of tumor-reactive T cell clones over time. Tumor-reactive TCRVβ clonotypes were determined using both FEST assay and HLA multimer sorting. Absolute numbers of tumor-reactive T cells at day 0 (TIL infusion) were inferred using infused TIL number divided by estimated blood volume.
